דסטיניב תרו 20 מג ישראל - עברית - Ministry of Health

דסטיניב תרו 20 מג

taro international ltd, israel - dasatinib - טבליות מצופות פילם - dasatinib 20 mg - dasatinib

דסטיניב תרו 50 מג ישראל - עברית - Ministry of Health

דסטיניב תרו 50 מג

taro international ltd, israel - dasatinib - טבליות מצופות פילם - dasatinib 50 mg - dasatinib

דסטיניב תרו 70 מג ישראל - עברית - Ministry of Health

דסטיניב תרו 70 מג

taro international ltd, israel - dasatinib - טבליות מצופות פילם - dasatinib 70 mg - dasatinib

דסטיניב תרו 80 מג ישראל - עברית - Ministry of Health

דסטיניב תרו 80 מג

taro international ltd, israel - dasatinib - טבליות מצופות פילם - dasatinib 80 mg - dasatinib

אזטימיב תרו 10 מג ישראל - עברית - Ministry of Health

אזטימיב תרו 10 מג

taro international ltd, israel - ezetimibe - טבליה - ezetimibe 10 mg - ezetimibe

פרקסיפרין 0.4 מ"ל/ 3800 IU AXA ישראל - עברית - Ministry of Health

פרקסיפרין 0.4 מ"ל/ 3800 iu axa

glaxo smith kline (israel) ltd - nadroparin calcium 3800 iu / 0.4 ml - solution for injection - nadroparin - prophylactic treatment of venous thromboembolic disease during surgery for patients presenting with moderate or high risk. treatment of constituted deep vein thrombosis. prevention of coagulation in the extra corporeal circuit during heamodialysis. the prophylaxis of thromboembolic disorders in high risk medical patients (respiratory failure and/or respiratory infection and/or cardiac failure) hospitalised in intensive care unit.

פרקסיפרין 0.3 מ"ל / 2850 AXa IU ישראל - עברית - Ministry of Health

פרקסיפרין 0.3 מ"ל / 2850 axa iu

glaxo smith kline (israel) ltd - nadroparin calcium 2850 iu / 0.3 ml - solution for injection - nadroparin - prophylactic treatment of venous thromboembolic disease during surgery for patients presenting with moderate or high risk. treatment of constituted deep vein thrombosis. prevention of coagulation in the extra corporeal circuit during haemodialysis. the prophylaxis of thromboembolic disorders in high risk medical patients (respiratory failure and/or respiratory infection and/or cardiac failure) hospitalised in intensive care unit.

פרקסיפרין 0.6 מ"ל/ 5700 IU AXA ישראל - עברית - Ministry of Health

פרקסיפרין 0.6 מ"ל/ 5700 iu axa

glaxo smith kline (israel) ltd - nadroparin calcium 5700 iu / 0.6 ml - solution for injection - nadroparin - prophylactic treatment of venous thromboembolic disease during surgery for patients presenting with moderate or high risk. treatment of constituted deep vein thrombosis. prevention of coagulation in the extra corporeal circuit during haemodialysis. the prophylaxis of thromboembolic disorders in high risk medical patients (respiratory failure and/or respiratory infection and/or cardiac failure) hospitalised in intensive care unit.

פרקסיפרין 0.8 מ"ל/7600 IU AXa ישראל - עברית - Ministry of Health

פרקסיפרין 0.8 מ"ל/7600 iu axa

glaxo smith kline (israel) ltd - nadroparin calcium 7600 iu / 0.8 ml - solution for injection - nadroparin - prophylactic treatment of venous thromboembolic disease during surgery for patients presenting with moderate or high risk. treatment of constituted deep vein thrombosis. prevention of coagulation in the extra corporeal circuit during haemodialysis. the prophylaxis of thromboembolic disorders in high risk medical patients (respiratory failure and/or respiratory infection and/or cardiac failure) hospitalised in intensive care unit.

נקסיום טבליות 20 מג ישראל - עברית - Ministry of Health

נקסיום טבליות 20 מג

taro international ltd, israel - esomeprazole - טבליה - esomeprazole 20 mg - esomeprazole - esomeprazole - nexium tablets are indicated for: gastroesophageal reflux disease (gerd): - treatment of erosive reflux esophagitis - long-term management of patients with healed esophagitis to prevent relapse - symptomatic treatment of gastroesophageal reflux disease (gerd). in combination with an appropriate antibacterial therapeutic regimen for the eradication of helicobacter pylori and: - healing of helicobacter pylori associated duodenal ulcer and - prevention of relapse of peptic ulcers in patients with helicobacter pylory associated ulcers. - healing of gastric ulcers associated with nsaid therapy. - prevention of gastric and duodenal ulcers associated with nsaid therapy in patients at risk.prolonged treatment after i.v induced prevention of rebleeding of peptic ulcers.